API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license LSVT-1701 (tonabacase) for further clinical development and commercialization.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: LSVT-1701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: $CHECK CHECK Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, Basilea will investigate SAL200 (tonabacase), a potential first-in-class clinical-stage antibacterial of the endolysin class, against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: SAL200
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 31, 2023
Details:
Under the agreement, iNtRON grants Basilea exclusive right for preclinical evaluation of the antibacterial bio-drug N-Rephasin SAL200 (tonabacase), a novel endolysin-based anti-staphylococcal drug formulated for injection.
Lead Product(s): Tonabacase
Therapeutic Area: Infections and Infectious Diseases Product Name: N-Rephasin SAL200
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 30, 2023